746 related articles for article (PubMed ID: 34377985)
1. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
Halatsch ME; Kast RE; Karpel-Massler G; Mayer B; Zolk O; Schmitz B; Scheuerle A; Maier L; Bullinger L; Mayer-Steinacker R; Schmidt C; Zeiler K; Elshaer Z; Panther P; Schmelzle B; Hallmen A; Dwucet A; Siegelin MD; Westhoff MA; Beckers K; Bouche G; Heiland T
Neurooncol Adv; 2021; 3(1):vdab075. PubMed ID: 34377985
[TBL] [Abstract][Full Text] [Related]
2. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Kast RE; Karpel-Massler G; Halatsch ME
Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540
[TBL] [Abstract][Full Text] [Related]
4. In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma.
Halatsch ME; Dwucet A; Schmidt CJ; Mühlnickel J; Heiland T; Zeiler K; Siegelin MD; Kast RE; Karpel-Massler G
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959641
[TBL] [Abstract][Full Text] [Related]
5. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Kast RE; Boockvar JA; Brüning A; Cappello F; Chang WW; Cvek B; Dou QP; Duenas-Gonzalez A; Efferth T; Focosi D; Ghaffari SH; Karpel-Massler G; Ketola K; Khoshnevisan A; Keizman D; Magné N; Marosi C; McDonald K; Muñoz M; Paranjpe A; Pourgholami MH; Sardi I; Sella A; Srivenugopal KS; Tuccori M; Wang W; Wirtz CR; Halatsch ME
Oncotarget; 2013 Apr; 4(4):502-30. PubMed ID: 23594434
[TBL] [Abstract][Full Text] [Related]
6. Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro.
Cao Q; Hajosch A; Kast RE; Loehmann C; Hlavac M; Fischer-Posovszky P; Strobel H; Westhoff MA; Siegelin MD; Wirtz CR; Halatsch ME; Karpel-Massler G
Br J Cancer; 2024 May; 130(8):1365-1376. PubMed ID: 38396172
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
10. MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.
Kast RE; Alfieri A; Assi HI; Burns TC; Elyamany AM; Gonzalez-Cao M; Karpel-Massler G; Marosi C; Salacz ME; Sardi I; Van Vlierberghe P; Zaghloul MS; Halatsch ME
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626167
[TBL] [Abstract][Full Text] [Related]
11. Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Saran F; Welsh L; James A; McBain C; Gattamaneni R; Jefferies S; Harris F; Pemberton K; Schaible J; Bender S; Cseh A; Brada M
J Neurooncol; 2021 Dec; 155(3):307-317. PubMed ID: 34787778
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
13. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.
Reardon DA; Nabors LB; Mason WP; Perry JR; Shapiro W; Kavan P; Mathieu D; Phuphanich S; Cseh A; Fu Y; Cong J; Wind S; Eisenstat DD;
Neuro Oncol; 2015 Mar; 17(3):430-9. PubMed ID: 25140039
[TBL] [Abstract][Full Text] [Related]
14. Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Elinzano H; Toms S; Robison J; Mohler A; Carcieri A; Cielo D; Donnelly J; Disano D; Vatketich J; Baekey J; Sturtevant A; MacKinnon K; Wood R; Safran H
Am J Clin Oncol; 2021 Feb; 44(2):49-52. PubMed ID: 33284237
[TBL] [Abstract][Full Text] [Related]
15. Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
Huang J; Campian JL; Gujar AD; Tsien C; Ansstas G; Tran DD; DeWees TA; Lockhart AC; Kim AH
J Neurooncol; 2018 May; 138(1):105-111. PubMed ID: 29374809
[TBL] [Abstract][Full Text] [Related]
16. Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
Gainer JL; Sheehan JP; Larner JM; Jones DR
J Neurosurg; 2017 Feb; 126(2):460-466. PubMed ID: 27177177
[TBL] [Abstract][Full Text] [Related]
17. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Groves MD; Puduvalli VK; Gilbert MR; Levin VA; Conrad CA; Liu VH; Hunter K; Meyers C; Hess KR; Alfred Yung WK
Br J Cancer; 2009 Aug; 101(4):615-20. PubMed ID: 19672263
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Kong DS; Lee JI; Kim JH; Kim ST; Kim WS; Suh YL; Dong SM; Nam DH
Neuro Oncol; 2010 Mar; 12(3):289-96. PubMed ID: 20167817
[TBL] [Abstract][Full Text] [Related]
19. A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy.
Huang J; Campian JL; Gujar AD; Tran DD; Lockhart AC; DeWees TA; Tsien CI; Kim AH
J Neurooncol; 2016 Jun; 128(2):259-66. PubMed ID: 26966095
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
